BANK OF AMERICA CORP /DE/ - AVALANCHE BIOTECHNOLOGIES IN ownership

AVALANCHE BIOTECHNOLOGIES IN's ticker is AAVL and the CUSIP is 05337G107. A total of 80 filers reported holding AVALANCHE BIOTECHNOLOGIES IN in Q1 2016. The put-call ratio across all filers is 6.56 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of AVALANCHE BIOTECHNOLOGIES IN
ValueSharesWeighting
Q1 2016$5,000
-99.4%
1,000
-98.8%
0.00%
Q4 2015$818,000
+6192.3%
85,917
+5372.4%
0.00%
Q3 2015$13,000
-98.9%
1,570
-97.9%
0.00%
Q2 2015$1,236,000
+123500.0%
76,114
+362347.6%
0.00%
Q1 2015$1,000
-99.6%
21
-99.5%
0.00%
Q4 2014$226,0004,1780.00%
Other shareholders
AVALANCHE BIOTECHNOLOGIES IN shareholders Q1 2016
NameSharesValueWeighting ↓
VHCP Management, LLC 1,102,735$5,701,0004.95%
GREAT POINT PARTNERS LLC 1,295,416$6,697,0002.40%
VHCP Management II, LLC 280,000$1,448,0000.95%
JW Asset Management, LLC 189,919$982,0000.64%
DAFNA Capital Management LLC 140,600$727,0000.63%
Wildcat Capital Management, LLC 235,264$1,216,0000.42%
Rhenman & Partners Asset Management AB 154,006$796,0000.16%
SABBY MANAGEMENT, LLC 540,632$2,795,0000.14%
KNOTT DAVID M 66,000$341,220,0000.09%
Numeric Investors LLC 984,309$5,089,0000.05%
View complete list of AVALANCHE BIOTECHNOLOGIES IN shareholders